After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona ...

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

The FDA approved labeling changes for elivaldogene autotemcel (eli-cel; Skysona), a one-time gene therapy for patients with early, active cerebral adrenoleukodystrophy (CALD), to reflect new safety ...

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

Net loss (GAAP) widened to $2.6 million, driven by increased expenses from the GPCR Therapeutics USA Inc. acquisition. Management issued a going concern warning, citing $7.9 million in cash and cash ...

REGENXBIO Inc. announced it will initiate a pivotal phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal ...

Neuroblastoma can be a particularly insidious cancer. In about half of all cases, tumors regress, even without therapy. In ...

Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune cle ...

Cancer survival has doubled in the past half a century, but around 167,000 people still die of the disease in the UK every ...

In this webinar, Martin Jarrold, Benjamin Clarke, and Rebecca D’Esposito will discuss the impact of charge detection mass ...

A study led by Roswell Park Comprehensive Cancer Center helps explain why a rare and hyper-aggressive subtype of kidney cancer is susceptible to immunotherapy—information that helped researchers ...

In medicine and biotechnology, the ability to evolve proteins with new or improved functions is crucial, but current methods ...